A Multicenter Phase I Dose Escalation Trial to Evaluate Safety and Tolerability of Intra-arterial Temozolomide for Patients with Advanced Extremity Melanoma Using Normothermic Isolated Limb Infusion

Annals of Surgical Oncology

Volumn 22, Issue 1, 2015, Pages 287-294

  Beasley, Georgia M ^a   Speicher, Paul ^a   Augustine, Christina K ^a,b   Dolber, Paul C ^a,b   Peterson, Bercedis L ^a   Sharma, Ketan ^a   Mosca, Paul J ^a   Royal, Richard ^c   Ross, Merrick ^c   Zager, Jonathan S ^d   Tyler, Douglas S ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATINE KINASE; MELPHALAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; MESSENGER RNA; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARM; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPARTMENT SYNDROME; CREATINE KINASE BLOOD LEVEL; DNA METHYLATION; DOSE LIMITING TOXICITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ERYTHRODERMA; FEMALE; GENE EXPRESSION ASSAY; HUMAN; HUMAN TISSUE; ISOLATED LIMB INFUSION; LEG; LYMPHEDEMA; MACULOPAPULAR RASH; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MOTOR NEUROPATHY; MULTICENTER STUDY; MUSCLE NECROSIS; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PROMOTER REGION; PROTEIN EXPRESSION; REGIONAL PERFUSION; TOXICOLOGICAL PARAMETERS; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COHORT ANALYSIS; FOLLOW UP; GENETICS; INTRAARTERIAL DRUG ADMINISTRATION; LIMB; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TISSUE DISTRIBUTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; COHORT STUDIES; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; TISSUE DISTRIBUTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84919773190     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3887-z     Document Type: Article

References (31)

1. Benckhuijsen C, Kroon BBR, van Geel AN, et al. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol. 1988;14:157.
2. Krementz ET, Ryan RF. Chemotherapy of melanoma of the extremities by perfusion: fourteen years’ clinical experience. Ann Surg. 1972;175:900.
3. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg. 1992;16:227.
4. Lejeune FJ, Ghanem GE. A simple and accurate new method for cytostatic dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination. Cancer Res. 1987;47:639.
5. Briele HA, Djuric M, Jung DT, et al. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res. 1985;45:1885–9.
6. Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg. 2012;214:245.
7. Sanki A, Kam PCA, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg. 2007;245:591–6.
8. Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol. 2010;24:4196–201.
9. Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the U.S. J Am Coll Surg. 2009;208:706–15.
10. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma: a 14-year experience. Ann Surg Oncol. 2008;15:3003–13.
11. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000;5:144–51.
12. Bleehen NM, Newlands ES, Lee SM, et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol. 1995;13:910–3.
13. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158–66.
14. Ueno T, Ko SH, Grubbs E, et al. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg. 2004;188:532–7.
15. Yoshimoto Y, Augustine CK, Yoo JS, et al. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. Mol Cancer Ther. 2007;6:1492–500.
16. Chowdhury SK, Laudicina D, Blumekrantz N, et al. An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma. J Pharmaceut Biomed Anal. 1995;19:659–68.
17. Augustine CK, Yoo JS, Potti AN, et al. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res. 2009;15:502–10. [Erratum in Clin Cancer Res. 2009;15:3240].
18. Zhang J, Stevens M, Bradshaw T. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2012;5:102–14.
19. Beasley GM, Riboh JC, Augustine CK, et al. A prospective multi-center phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion (M-ILI) in patients with advanced extremity melanoma. J Clin Oncol. 2011;29:1210–5.
20. Beasley GM, Coleman AP, McMahon N, et al. A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. Ann Surg Oncol. 2012;19:3896–905.
21. Beasley GM, Shetty G, Sparks S, et al. Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion. Ann Surg Oncol. 2013;20:1128–35.
22. McMahon N, Cheng TY, Beasley GM, et al. Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol. 2009;16:953–61.
23. Santillan AA, Delman KA, Beasley GM, et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion: a multi-institutional analysis. Ann Surg Oncol. 2009;16:2570–8.
24. Kishida Y, Nastume A, Toda H. Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas. Tumor Biol. 2012;33:373–81.
25. Hayashi H, Yazawa T, Okudela K, et al. Inactivation of O6-methylguanine DNA methyltransferase in human lung adenocarncinoma relates to high grade histology and worse prognosis among smokers. Jpn J Cancer Res. 2002;93:184–9.
26. Donepudi M, Jovasevic VM, Raychaudhuri P, et al. Melphalan induced up regulation of B7-1 surface expression of normal splenic B cells. Cancer Immunother. 2003;52:162–70.
27. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54–61.
28. Hanks BA, Holtzhausen A, Evans KS, et al. Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest. 2013;123:3925–40.
29. Chai CY, Deneve JL, Beasley GM, et al. A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol. 2012;19:1637–43.
30. Kroon HM, Lin DY, Kam PC, Thompson JF. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer. 2009;115:1932–40.
31. Ueno T, Ko SH, Yashimoto Y, et al. A novel regional strategy for extremity melanoma using modulation of chemotherapy resistance: intra-arterial temozolomide plus systemic O6-benzylguanine. Mol Cancer Ther. 2006;5:732–8.